Proteomics International Laboratories is showcasing its latest diagnostic milestones for endometriosis and oesophageal cancer in front of Australia and New Zealand’s field-leading researchers at a symposium in Victoria.
The Company says its latest clinical results demonstrate “robust evidence” for the inclusion of its biomarker panels in its bid to produce breakthrough diagnostic blood tests for both of the severe conditions. It is this week presenting the results from its research with a second independent patient group to the 29th annual Lorne Proteomics Symposium.
Article: Proteomics takes forward step with blood test diagnosis
